BUZZ-BridgeBio gains as Q1 sales of heart condition drug beat estimates

Reuters

Apr 30, 2025

** Shares of drugmaker BridgeBio Pharma BBIO.O rise 7.08% to $39 after market

** Co posts Q1 Attruby sales of $36.7 million, beating estimates of $13.10 million, according to data compiled by LSEG

** Attruby is used to treat adults with transthyretin amyloid cardiomyopathy (ATTR-CM), in which faulty transthyretin proteins accumulate in the heart and can cause the organ to fail

** As of April 25, 2,072 unique patient prescriptions for Attruby have been written by 756 healthcare providers since FDA approval in November 2024

** Attruby launch continues to be strong so far and has raised market expectations — BMO Capital Markets

** Stock up ~32% YTD

(Reporting by Sriparna Roy in Bengaluru)

((Sriparna.Roy@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2531130887"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2531130887\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2531130887?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-30 05:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2531130887","market":"us","top_or_hot":-1,"title":"BUZZ-BridgeBio gains as Q1 sales of heart condition drug beat estimates","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-BridgeBio gains as Q1 sales of heart condition drug beat estimates</title></head><body><p>** Shares of drugmaker BridgeBio Pharma <span>BBIO.O</span> rise 7.08% to $39 after market</p><p>** Co <span>posts</span> Q1 Attruby sales of $36.7 million, beating estimates of $13.10 million, according to data compiled by LSEG</p><p>** Attruby is used to <span>treat</span> adults with transthyretin amyloid cardiomyopathy (ATTR-CM), in which faulty transthyretin proteins accumulate in the heart and can cause the organ to fail</p><p>** As of April 25, 2,072 unique patient prescriptions for Attruby have been written by 756 healthcare providers since FDA approval in November 2024</p><p>** Attruby launch continues to be strong so far and has raised market expectations — BMO Capital Markets</p><p>** Stock up ~32% YTD</p><p>(Reporting by Sriparna Roy in Bengaluru)</p><p>((Sriparna.Roy@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-BridgeBio gains as Q1 sales of heart condition drug beat estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-BridgeBio gains as Q1 sales of heart condition drug beat estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-04-30 05:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-BridgeBio gains as Q1 sales of heart condition drug beat estimates</title></head><body><p>** Shares of drugmaker BridgeBio Pharma <span>BBIO.O</span> rise 7.08% to $39 after market</p><p>** Co <span>posts</span> Q1 Attruby sales of $36.7 million, beating estimates of $13.10 million, according to data compiled by LSEG</p><p>** Attruby is used to <span>treat</span> adults with transthyretin amyloid cardiomyopathy (ATTR-CM), in which faulty transthyretin proteins accumulate in the heart and can cause the organ to fail</p><p>** As of April 25, 2,072 unique patient prescriptions for Attruby have been written by 756 healthcare providers since FDA approval in November 2024</p><p>** Attruby launch continues to be strong so far and has raised market expectations — BMO Capital Markets</p><p>** Stock up ~32% YTD</p><p>(Reporting by Sriparna Roy in Bengaluru)</p><p>((Sriparna.Roy@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BBIO","symbol_name":"BridgeBio Pharma, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nL4N3R72R6:1","article_id":"2531130887","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2531130887","pubTimestamp":1745962999,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-BridgeBio gains as Q1 sales of heart condition drug beat estimates** Shares of drugmaker BridgeBio Pharma BBIO.O rise 7.08% to $39 after market** Co posts Q1 Attruby sales of $36.7 million, beating estimates of $13.10 million, according to data compiled by LSEG** Attruby is used to treat adults with transthyretin amyloid cardiomyopathy , in which faulty transthyretin proteins accumulate in the heart and can cause the organ to fail** As of April 25, 2,072 unique patient prescriptions for Attruby have been written by 756 healthcare providers since FDA approval in November 2024** Attruby launch continues to be strong so far and has raised market expectations — BMO Capital Markets** Stock up ~32% YTD","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"BBIO":"BridgeBio Pharma, Inc."},"translate_title":"BUZZ-BridgeBio第一季度心脏病药物销售额超出预期，股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BBIO":0.9},"content_text":"BUZZ-BridgeBio gains as Q1 sales of heart condition drug beat estimates** Shares of drugmaker BridgeBio Pharma BBIO.O rise 7.08% to $39 after market** Co posts Q1 Attruby sales of $36.7 million, beating estimates of $13.10 million, according to data compiled by LSEG** Attruby is used to treat adults with transthyretin amyloid cardiomyopathy (ATTR-CM), in which faulty transthyretin proteins accumulate in the heart and can cause the organ to fail** As of April 25, 2,072 unique patient prescriptions for Attruby have been written by 756 healthcare providers since FDA approval in November 2024** Attruby launch continues to be strong so far and has raised market expectations — BMO Capital Markets** Stock up ~32% YTD(Reporting by Sriparna Roy in Bengaluru)((Sriparna.Roy@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}